{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T23:28:01Z","timestamp":1783639681951,"version":"3.55.0"},"reference-count":35,"publisher":"Pan American Health Organization","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Panam Salud Publica"],"abstract":"<jats:p>Se presenta un consenso latinoamericano que permite estandarizar las definiciones de los diferentes niveles de resistencia a los antimicrobianos en bacterias de importancia en salud p\u00fablica. Se describen los criterios de inclusi\u00f3n y exclusi\u00f3n para las metodolog\u00edas a utilizar y para los antibi\u00f3ticos a incluir (por disponibilidad, relevancia y existencia de puntos de corte). Como propuesta piloto se eligieron tres microorganismos gramnegativos de gran impacto en el ambiente hospitalario (Klebsiella pneumoniae, Pseudomonas aeruginosa y Acinetobacter spp.). La falta de puntos de corte para ciertos antibi\u00f3ticos (por ejemplo, tigeciclina, fosfomicina y colistina), claves para el tratamiento de infecciones causadas por estos pat\u00f3genos que presentan multirresistencia o resistencia extendida, llev\u00f3 a la necesidad de discutir y consensuar puntos de corte provisorios para la vigilancia de la resistencia a estos f\u00e1rmacos. Se abord\u00f3 y consensu\u00f3 tambi\u00e9n el uso de pruebas de sensibilidad alternativas a los m\u00e9todos aprobados por las gu\u00edas internacionales, de aplicaci\u00f3n m\u00e1s sencilla como pruebas de rutina en los laboratorios de bacteriolog\u00eda cl\u00ednica. El principal beneficio de este documento es proporcionar a los laboratorios latinoamericanos un marco estandarizado y consensuado para la identificaci\u00f3n y la vigilancia constante y unificada de microorganismos resistentes. Las recomendaciones incluidas en este documento son el resultado consensuado por los representantes de los laboratorios nacionales de referencia de los pa\u00edses que integran la Red Latinoamericana de Vigilancia de la Resistencia a los Antibi\u00f3ticos coordinada por la Organizaci\u00f3n Panamericana de la Salud.<\/jats:p>","DOI":"10.26633\/rpsp.2019.65","type":"journal-article","created":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T13:58:01Z","timestamp":1566482281000},"page":"1-8","source":"Crossref","is-referenced-by-count":19,"title":["Consenso latinoamericano para definir, categorizar y notificar pat\u00f3genos multirresistentes, con resistencia extendida o panresistentes"],"prefix":"10.26633","author":[{"given":"Mar\u00eda Antonieta","family":"Jim\u00e9nez Pearson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Galas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Corso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan C.","family":"Hormaz\u00e1bal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Duarte Valderrama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuris","family":"Salgado Marcano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Ram\u00f3n-Pardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Melano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11167","published-online":{"date-parts":[[2019]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Baquero F. The 2010 Garrod Lecture: The dimensions of evolution in antibiotic resistance: ex unibus plurum et ex pluribus unum. J Antimicrob Chemother. 2011;66:1659-72.","DOI":"10.1093\/jac\/dkr214"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Wellington EM, Boxall AB, Cross P, Feil EJ, Gaze WH, Hawkey PM, et al. The role of the natural environment in the emergence of antibiotic resistance in gram-negative bacteria. Lancet Infect Dis. 2013;13(12)70317-1","DOI":"10.1016\/S1473-3099(12)70317-1"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Carlet J, Jarlier V, Harbarth S, Voss A, Goossens H, Pittet D for the Participants of the 3rd World Healthcare-Associated Infections Forum. Ready for a world without antibiotics? The pensi\u00e8res antibiotic resistance call to action. Antimicrob Resist Infect Control. 2012;1:11. https:\/\/doi.org\/10.1186\/2047-2994-1-11","DOI":"10.1186\/2047-2994-1-11"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Van Boeckel TP, Brower C, Gilbert M, Grenfell BT, Levin SA, Robinson TP, et al. Global trends in antimicrobial use in food animals. Proc Natl Acad Sci USA. 2015;112(18):5649-54. doi: 10.1073\/pnas.1503141112","DOI":"10.1073\/pnas.1503141112"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Tang KL, Caffrey NP, N\u00f3brega DB, Cork SC, Ronksley PE, Barkema HW, et al. Restricting the use of antibiotics in food-producing animals and its associations with antibiotic resistance in food-producing animals and human beings: a systematic review and meta-analysis. Lancet Planet Health. 2017;1(17)30141-9","DOI":"10.1016\/S2542-5196(17)30141-9"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Chen L, Todd R, Kiehlbauch J, Walters M, Kallen A. Notes from the field: pan-resistant New Delhi Metallo-\u00df-lactamase-producing Klebsiella pneumoniae-Washoe County, Nevada, 2016. MMWR. 2017;66(1):33. doi: 10.15585\/mmwr.mm6601a7","DOI":"10.15585\/mmwr.mm6601a7"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Fernandez P, Martens E. Antibiotics in late clinical development. Biochem Pharmacol. 2017;133:152-63. http:\/\/dx.doi.org\/10.1016\/j.bcp.2016.09.025","DOI":"10.1016\/j.bcp.2016.09.025"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Falagas ME, Karageorgopoulos DE. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among gram-negative bacilli: need for international harmonization in terminology. Clin Infect Dis. 2008;46:1121-2.","DOI":"10.1086\/528867"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Paterson DL, Doi Y. Reply to Falagas and Karageorgopoulos. Clin Infect Dis. 2008;46:1122-3.","DOI":"10.1086\/528868"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268-81.","DOI":"10.1111\/j.1469-0691.2011.03570.x"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"German GJ, Jamieson FB, Gilmour M, Almohri H, Bullard J, Domingo MC, et al.. Interim recommendations for the reporting of extensively drug resistant and pan drug resistant isolates of Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter spp. and Stenotrophomonas maltophilia. Can Comm Dis Rep. 2016;42:91-7.","DOI":"10.14745\/ccdr.v42i04a04"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"German GJ, Gilmour M, Tipples G, Adam HJ, Almohri H, Bullard J, et al. . Canadian recommendations for laboratory interpretation of multiple or extensive drug resistance in clinical isolates of Enterobacteriaceae, Acinetobacter species and Pseudomonas aeruginosa. Can Commun Dis Rep. 2018;44(https:\/\/doi.org\/10.14745\/ccdr.v44i01a07","DOI":"10.14745\/ccdr.v44i01a07"},{"key":"ref13","unstructured":"Organizaci\u00f3n Mundial de la Salud. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics; 2017. Disponible en: http:\/\/www.who.int\/medicines\/publications\/global-priority-list-antibiotic-resistant-bacteria\/en\/"},{"key":"ref14","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; approved standard-29th ed. CLSI document M100S. Wayne, PA: CLSI; 2019."},{"key":"ref15","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters; 2019. Disponible en: http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_9.0_Breakpoint_Tables.pdf"},{"key":"ref16","unstructured":"U.S. Food and Drug Administration. Antibacterial susceptibility test interpretive criteria; 2017. Disponible en: https:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/ucm575163.htm"},{"key":"ref17","unstructured":"Clinical and Laboratory Standards Institute-European Committee on Antimicrobial Susceptibility Testing (CLSI-EUCAST) Polymyxin Breakpoints Working Group. Recommendations for MIC determination of colistin (polymyxin E) as recommended by the joint CLSI-EUCAST Polymyxin Breakpoints Working Group; 2016. Disponible en: http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/General_documents\/Recommendations_for_MIC_determination_of_colistin_March_2016.pdf"},{"key":"ref18","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Guidance document on tigecycline dosing in association with revision of breakpoints for Enterobacteriaceae and other species with an \u201cintermediate\u201d category; 2018. Disponible en: http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/General_documents\/Tigecycline_Guidance_document_20181223.pdf"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Paster\u00e1n F, Lucero C, Rapoport M, Guerriero L, Barreiro I, Albornoz E, et al. Tigecycline and intravenous fosfomycin zone breakpoints equivalent to the EUCAST MIC criteria for Enterobacteriaceae. J Infect Dev Ctries. 2012;6(5):452-6.","DOI":"10.3855\/jidc.2238"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Ito R, Mustapha MM, Tomich AD, Callaghan JD, McElheny CL, Mettus RT, et al. . Widespread fosfomycin resistance in Gram-negative bacteria attributable to the chromosomal fosA gene. mBio. 2017;8:e00749-17. https:\/\/doi.org\/10.1128\/mBio.00749-17","DOI":"10.1128\/mBio.00749-17"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Klontz EH, Tomich AD, G\u00fcnther S, Lemkul JA, Deredge D, Silverstein Z, et al. Structure and dynamics of FosA-mediated fosfomycin resistance in Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother. 2017;61:e01572-17. https:\/\/doi.org\/10.1128\/AAC.01572-17","DOI":"10.1128\/AAC.01572-17"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Lo-Ten-Foe JR, de Smet AM, Diederen BM, Kluytmans JA, van Keulen PH. Comparative evaluation of the VITEK 2, disk diffusion, Etest, broth microdilution, and agar dilution susceptibility testing methods for colistin in clinical isolates, including heteroresistant Enterobacter cloacae and Acinetobacter baumannii strains. Antimicrob Agents Chemother. 2007;51:3726\u201330.","DOI":"10.1128\/AAC.01406-06"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Behera B, Mathur P, Das A, Kapil A, Gupta B, Bhoi S, et al. Evaluation of susceptibility testing methods for polymyxin. Int J Infect Dis. 2010;14:e596-e601.","DOI":"10.1016\/j.ijid.2009.09.001"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Hindler JA, Humphries RM. Colistin MIC variability by method for contemporary clinical isolates of multidrug-resistant Gram-negative bacilli. J Clin Microbiol. 2013;51:1678-84.","DOI":"10.1128\/JCM.03385-12"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Jayol A, Nordmann P, Andr\u00e9 C, Poirel L, Dubois V. Evaluation of three broth microdilution systems to determine colistin susceptibility of Gram-negative bacilli. J Antimicrob Chemother. 2018;73(5):1272-8. doi: 10.1093\/jac\/dky012","DOI":"10.1093\/jac\/dky012"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Lee SY, Shin JH, Lee K, Joo MY, Park KH, Shin MG, et al. Comparison of the Vitek 2, MicroScan, and Etest methods with the agar dilution method in assessing colistin susceptibility of bloodstream isolates of Acinetobacter species from a Korean university hospital. J Clin Microbiol. 2013;51:1924-6.","DOI":"10.1128\/JCM.00427-13"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Perez LR. Evaluation of polymyxin susceptibility profile among KPC-producing Klebsiella pneumoniae using Etest and MicroScan WalkAway automated system. APMIS 2015;123:951-4.","DOI":"10.1111\/apm.12438"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Jayol A, Nordmann P, Lehours P, Poirel L, Dubois V. Comparison of methods for detection of plasmid-mediated and chromosomally encoded colistin resistance in Enterobacteriaceae. Clin Microbiol Infect. 2018;24(2):175-9.","DOI":"10.1016\/j.cmi.2017.06.002"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Simner PJ, Bergman Y, Trejo M, Roberts AA, Marayan R, Tekle T, et al. Two-site evaluation of the colistin broth disk elution test to determine colistin in vitro activity against Gram-negative bacilli. J Clin Microbiol. 2019;57:e01163-18. https:\/\/doi.org\/10.1128\/JCM.01163-18.","DOI":"10.1128\/JCM.01163-18"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Poirel L, Jayol A, Nordmann P. Polymyxins: antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes. Clin Microbiol Rev. 2017;30:557-96.","DOI":"10.1128\/CMR.00064-16"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Tan TY, Ng SY. Comparison of Etest, Vitek and agar dilution for susceptibility testing of colistin. Clin Microbiol Infect. 2007;13:541-4.","DOI":"10.1111\/j.1469-0691.2007.01708.x"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Chew KL, La M-V, Lin RTP, Teo JWP. Colistin and polymyxin B susceptibility testing for carbapenem-resistant and mcr positive Enterobacteriaceae: comparison of Sensititre, MicroScan, Vitek 2, and Etest with broth microdilution. J Clin Microbiol. 2017;55(https:\/\/doi.org\/10.1128\/JCM.00268-17","DOI":"10.1128\/JCM.00268-17"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Vasoo S. Susceptibility testing for the polymyxins: two steps back, three steps forward? J Clin Microbiol. 2017;55(9):2573-82. doi: 10.1128\/JCM.00888-17","DOI":"10.1128\/JCM.00888-17"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Matuschek E, \u00c5hman J, Webster C, Kahlmeter G. Antimicrobial susceptibility testing of colistin - evaluation of seven commercial MIC products against standard broth microdilution for Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter spp. Clin Microbiol Infect. 2018;24(8):865-70. doi: 10.1016\/j.cmi.2017.11.020","DOI":"10.1016\/j.cmi.2017.11.020"},{"key":"ref35","unstructured":"Servicio Antimicrobianos (LRR)- Instituto Nacional de Enfermedades Infecciosas-Administraci\u00f3n Nacional de Laboratorios e Institutos (INEI-ANLIS) \u201cDr. Carlos G. Malbr\u00e1n\u201d (INEI ANLIS) \u201cDr. Carlos G. Malbr\u00e1n. Desaf\u00edos en los m\u00e9todos de evaluaci\u00f3n de la sensibilidad a las polimixinas (colistina\/polimixina B). Bolet\u00edn Informativo No. 30-setiembre 2017. Disponible en: http:\/\/antimicrobianos.com.ar\/ATB\/wp-content\/uploads\/2017\/09\/Boletin-PCC-LAT-Nro.30-Metodos-de-Evaluacion-Sensibilidad-a-POLIMIXINAS-Sep-20171.pdf"}],"container-title":["Revista Panamericana de Salud P\u00fablica"],"original-title":[],"link":[{"URL":"https:\/\/iris.paho.org\/bitstream\/handle\/10665.2\/51470\/v43e652019.pdf?sequence=1&isAllowed=y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T14:53:13Z","timestamp":1645714393000},"score":1,"resource":{"primary":{"URL":"https:\/\/iris.paho.org\/handle\/10665.2\/51470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":35,"URL":"https:\/\/doi.org\/10.26633\/rpsp.2019.65","relation":{},"ISSN":["1020-4989","1680-5348"],"issn-type":[{"value":"1020-4989","type":"print"},{"value":"1680-5348","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]}}}